RFB01016 senolytic drug program
preclinicalDevelop a senolytic therapy that removes senescent cells to address age-related diseases and healthy aging, with stated areas including chronic kidney disease, diabetes, cardiovascular disease, liver fibrosis, neurodegenerative diseases, sarcopenia, immunosenescence, lung diseases, osteoarthritis, and frailty.
Senolytic drug candidate targeting senescent cells.
Reported preclinical evidence of lifespan and healthspan extension, neuromuscular function restoration, and reduction of senescent cells in several tissues; Rockfish Bio also received 2025 commercialization/start-up awards for its senolytic drug candidates.
Preclinical studies are described as extending health and life span, improving neuromuscular function, and reducing senescent cells in several tissues.